Physician profile
Mark Mann
NPI 1225291123
$2,841.34
in general payments reported to CMS, 2019-2025
23 companies · $700 in 2025
The $700 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $150 · 2021: $14.39 · 2022: $425 · 2023: $1,078 · 2024: $474 · 2025: $700.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,002 · Honoraria: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,001.85 |
| Honoraria | $250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $488.78 | 2022-2025 | |
| Myriad Genetic Laboratories, INC. | $357.13 | 2023-2025 | Myrisk, Prolaris |
| Cook Incorporated | $250.00 | 2023 | |
| Boston Scientific Corporation | $217.94 | 2019-2025 | Ams 700 |
| Janssen Biotech, INC. | $206.27 | 2021-2025 | Erleada |
| Angiodynamics, INC. | $192.37 | 2022 | |
| Coloplast Corp | $168.29 | 2023-2025 | Titan |
| Axonics, INC. | $161.73 | 2023-2024 | Axonics, Bulkamid |
| Sumitomo Pharma America, INC. | $134.78 | 2023-2025 | Gemtesa, Orgovyx |
| Astrazeneca Pharmaceuticals Lp | $120.54 | 2024 | Lynparza |
| Astellas Pharma US INC | $89.73 | 2019 | |
| Abbvie INC. | $80.95 | 2023-2025 | |
| Bioprotect Medical, INC. | $57.02 | 2025 | Bioprotect Balloon Implant System |
| 180 Medical, INC. | $52.56 | 2025 | |
| C. R. Bard, INC. & Subsidiaries | $45.14 | 2025 | Bard Urinary Drainage Bag, Bardex I.C. Criticore Foley Tray Bardex Temperature-Sensing Foley Catheter |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Palette Life Sciences, INC. | $39.79 | 2022 | |
| Olympus America INC. | $39.66 | 2025 | Itind System |
| Bluewind Medical | $29.97 | 2025 | |
| Dentsply Ih Ab | $25.87 | 2024 | Lofric |
| Progenics Pharmaceuticals, INC. | $22.43 | 2025 | |
| Abc Home Medical Supply, INC. | $22.17 | 2024 | |
| Merck Sharp & Dohme LLC | $21.22 | 2025 | Keytruda |
| Urogen Pharma, INC. | $17.00 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.